编号：2022-004 特定对象调研 分析师会议 媒体采访 业绩说明会 新闻发布会 路演活动 现场参观 其他（电话会议） 投资者关系活动 类别 参与单位名称及 人员姓名 申万宏源证券张静含，申万宏源证券陈烨远，嘉实基金邓云龙，嘉实 基金牛歌，嘉实基金黄福大。 时间 2022 年 11 月 18 日 16:00-17:30 地点 网络电话会议 上市公司接待人 员姓名 董事长王凝宇先生，董事会秘书缪飞先生，证券事务代表叶俞飞先生。 投资者关系活动主要内容介绍 一、问答环节 1. 我们观察到过去几年镇痛泵在无痛分娩和术后镇痛领域的应用在不断的扩大、渗透率 在提升，但近两年随着出生率有所下滑，疫情对手术量的持续影响包括今年医保余额不 足的情况下，请问王董事长您如何看待镇痛泵现在和未来的市场趋势？ 答：镇痛泵是一种精确、持续、微量给药的输液医疗设备，包括医生控制给药、患者控 制给药、陪护控制给药等多种方式。产品包括无线镇痛管理系统、微电脑驱动装置和一 次性使用的输液装置，应用场景主要是术后镇痛、分娩镇痛、癌性镇痛、肿瘤化疗给药 等，同时公司是参与"便携式电动输注泵"行业标准编制的唯一企业单位。 从市场容量来看，术后镇痛 ...

证券代码：300753 证券简称：爱朋医疗 江苏爱朋医疗科技股份有限公司 投资者关系活动记录表 编号：2022-002 | --- | --- | --- | |---------------------------------|----------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------| | | | | | 投资者关系活动 类 ...

证券代码：300753 证券简称：爱朋医疗 江苏爱朋医疗科技股份有限公司 投资者关系活动记录表 编号：2022-003 | --- | --- | --- | --- | |---------------------------------------------|-------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ...

Group 1: Company Overview - Aipeng Medical focuses on pain management and nasal cavity management, with a revenue of 717.2 million yuan in 2021, a 27% increase after excluding share-based payments [1] - The company is recognized as a national-level specialized and innovative "little giant" enterprise [1] - The main product, the electronic drug pump, is used for postoperative pain management and has a market size of approximately 15 billion yuan in 2021 [1] Group 2: Market Potential - The estimated market size for pain management products is projected to reach 30 billion yuan by 2026, with significant potential in day surgery, ICU, and painless examinations [1] - The nasal cavity management product, a saline nasal spray, has sold over 30 million bottles, capturing the largest market share [2] - The COVID-19 pandemic has increased the focus on nasal care, as nasal washing can reduce viral load and transmission [2] Group 3: Clinical Research and Development - Clinical observations are being conducted in Shanghai and Shenzhen, with a focus on the effectiveness of nasal washing in preventing COVID-19 [3] - Initial data from clinical studies is optimistic, with results expected to be published in high-impact journals later in the year [2] - The company is planning to expand its product indications and market promotion based on clinical research outcomes [3] Group 4: Marketing and Consumer Engagement - The company is actively promoting its products through various channels, including online platforms and educational initiatives [3] - There is a strategy to enhance consumer recognition and loyalty through clinical exposure and online sales [4] - The company aims to leverage social media platforms like Douyin for product promotion, pending regulatory approvals [6] Group 5: Financial and Operational Insights - The company reported that sales in Shanghai, which account for about 15% of total sales, were significantly impacted by the pandemic [4] - The production base in Jiangsu has not faced major disruptions, although logistics have experienced some delays [4] - The company is preparing for potential challenges related to production capacity and market competition as demand for nasal care products increases [4]

江苏爱朋医疗科技股份有限公司 2022 年第三季度报告 证券代码：300753 证券简称：爱朋医疗 公告编号：2022-061 江苏爱朋医疗科技股份有限公司 2022 年第三季度报告 本公司及董事会全体成员保证信息披露内容真实、准确和完整，不存在任何虚 假记载、误导性陈述或者重大遗漏。 重要内容提示： 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不存在虚假记载、误导性陈述或重 大遗漏，并承担个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报告中财务信息的真实、准确、 完整。 3.第三季度报告是否经过审计 □是 否 - 1 - 江苏爱朋医疗科技股份有限公司 2022 年第三季度报告 一、主要财务数据 （一） 主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □是 否 □适用 不适用 公司不存在将《公开发行证券的公司信息披露解释性公告第 1 号——非经常性损益》中列举的非经常性损益项目界定为 经常性损益的项目的情形。 - 2 - | | 本报告期 | 本报告期比上年同期增减 | 年初至报告期末 | 年初至报告期 ...

Financial Performance - The company reported a total revenue of RMB 100 million for the first half of 2022, representing a year-on-year increase of 15%[1] - The company's revenue for the first half of 2022 was ¥142,693,149.89, a decrease of 33.26% compared to ¥213,797,143.13 in the same period last year[22] - The net profit attributable to shareholders was a loss of ¥24,386,004.27, representing a decline of 165.58% from a profit of ¥37,184,403.89 in the previous year[22] - The net cash flow from operating activities was -¥56,467,615.15, a significant decrease of 220.17% compared to -¥17,636,569.58 in the same period last year[22] - The basic earnings per share were -¥0.1935, down 165.58% from ¥0.2950 in the previous year[22] - The company reported a weighted average return on equity of -3.18%, a decrease of 8.08% from 4.90% in the previous year[22] - The company’s cash and cash equivalents decreased by 9.89% to ¥181,305,095.62, down from ¥274,662,850.56, mainly due to reduced sales revenue[82] - The company’s sales expenses increased by 27.87% to ¥58,066,035.33, attributed to higher online promotion and salary costs[74] - The company’s financial expenses decreased significantly by 78.15% to -¥608,932.48, mainly due to reduced interest income from structured deposits[75] - The company reported a net profit of 6,324,185.18 for its subsidiary, Aipu Science, with total assets of 56,667,285.89 and net assets of 47,581,234.69[107] Research and Development - The company plans to invest RMB 20 million in R&D for new medical devices in the upcoming year[1] - The company invested CNY 21.2016 million in R&D during the reporting period, representing a year-on-year increase of 56.11%[51] - The company is collaborating with universities such as Sydney University and Nanjing University to develop innovative pain management technologies, including a portable closed-loop anesthesia and analgesia device[52] - The company has made progress in developing a pain assessment algorithm based on electrophysiological data, aiming to establish a leading domestic and international pain assessment device[53] - The company is developing a community/home pain management system utilizing 5G technology, which is currently in the design phase[53] - The company has launched a smart patient-controlled analgesia system, enhancing safety for patients and caregivers[55] - The company is working on a second-generation anesthesia depth monitor to improve product competitiveness[52] - The company is developing a closed-loop anesthesia system that integrates depth feedback information, aiming to provide an innovative smart anesthesia product[55] Market Expansion and Strategy - The company has set a revenue target of RMB 250 million for the full year 2022, which would represent a growth of 20% year-on-year[1] - The company is expanding its market presence in Southeast Asia, aiming for a 10% market share by the end of 2023[1] - The company is actively expanding its ecosystem in the pain management and upper respiratory tract management sectors, emphasizing innovation in its product offerings[38] - The company is focused on expanding its product offerings and improving technology in pain management and anesthesia monitoring[16] - The company aims to continue enhancing market share through academic collaboration, channel development, and public education efforts[71] - The company is actively exploring the health sleep market in collaboration with a well-known international sleep brand, aiming to expand its product applications[45] Product Development and Offerings - The company is focusing on the development of pain management solutions, with a projected launch of a new product line in Q4 2022[1] - The company has introduced various medical products, including PCA pumps and anesthesia depth monitors, to enhance pain management and monitoring capabilities[16] - The company launched a new product, a disposable saline nasal rinse, aimed at patients with nasal diseases, enhancing its clinical application portfolio[45] - The company expanded the indications for its main product, the nasal care spray, to include "improving nasal congestion and runny nose symptoms in patients with acute upper respiratory infections"[45] - The company is focused on expanding its product line into the sleep market with new products such as a snoring management system and a snoring diagnosis algorithm[55] Risk Management - The company has identified key risks including regulatory changes and supply chain disruptions, and is implementing strategies to mitigate these risks[1] - The company is facing risks from national policies affecting the medical device industry, particularly due to the implementation of centralized procurement for high-value medical consumables[108] - The company anticipates that the implementation of low-value consumables centralized procurement may impact its sales model and market dynamics[99] - The company will actively follow and research centralized procurement policies to enhance its market access capabilities and maintain competitive advantages[109] Corporate Governance and Social Responsibility - The company has not distributed cash dividends or bonus shares for the current fiscal year[1] - The company actively engaged in social responsibility initiatives, including supporting underprivileged groups and donating educational supplies to children in need[130] - The company donated over 190,000 bottles of nasal saline spray and medical masks to frontline healthcare workers and students during the pandemic[131] - The company emphasizes transparency and fairness in information disclosure to protect shareholder and investor rights[126] - The company has implemented a talent development strategy and employee care mechanisms, enhancing team cohesion and employee satisfaction during the pandemic[129] Financial Management and Investments - The total investment amount for the reporting period was ¥156,554,152.34, a decrease of 39.27% compared to ¥257,766,009.41 in the same period last year[86] - The company made a significant equity investment of ¥3,000,000.00 in a medical device manufacturer, holding a 23.08% stake, with a reported loss of ¥57,324.92[88] - The company has invested ¥479,771.11 in the construction of a medical industry park, with a cumulative actual investment of ¥112,043,937.69[90] - The company has not engaged in any derivative investments or entrusted loans during the reporting period[103][104] - The company has not disclosed any ongoing significant non-equity investments during the reporting period[89] Shareholder Information - The controlling shareholder, Wang Ningyu, reduced his stake by 2.44 million shares, accounting for 1.94% of the total share capital[153] - The total number of common shareholders at the end of the reporting period is 10,807[163] - The total number of shares pledged by major shareholders is substantial, with Wang Ningyu pledging 17,135,844 shares[166] - The company has not conducted any repurchase agreements among the top 10 shareholders during the reporting period[165] - The company has not reported any impacts on financial metrics such as earnings per share due to the share changes[159]

Report Cover and Disclaimer [Important Content Notice](index=1&type=section&id=Important%20Content%20Notice) This quarterly report is unaudited, but the company's board of directors, supervisory board, and senior management guarantee the truthfulness, accuracy, and completeness of the report content, and assume corresponding legal responsibilities - The Board of Directors, Supervisory Board, and senior management guarantee the truthfulness, accuracy, and completeness of the quarterly report, free from false records, misleading statements, or major omissions[3](index=3&type=chunk) - The company's responsible person, head of accounting, and head of accounting department declare and guarantee the truthfulness, accuracy, and completeness of the financial information[3](index=3&type=chunk) - The first quarterly report is unaudited[4](index=4&type=chunk) I. Major Financial Data [(1) Major Accounting Data and Financial Indicators](index=1&type=section&id=%281%29%20Major%20Accounting%20Data%20and%20Financial%20Indicators) The company's operating revenue for Q1 2022 decreased by 28.85% year-on-year, with net profit attributable to shareholders turning from profit to loss, a 157.05% decrease year-on-year, and basic earnings per share at -0.0872 CNY/share Major Accounting Data and Financial Indicators for Q1 2022 | Indicator | Current Period (CNY) | Prior Period (CNY) | Change from Prior Period | | :--- | :--- | :--- | :--- | | Operating Revenue | 72,794,357.61 | 102,316,781.63 | -28.85% | | Net Profit Attributable to Shareholders of Listed Company | -10,987,817.03 | 19,258,855.13 | -157.05% | | Net Profit Attributable to Shareholders of Listed Company (Excluding Non-Recurring Gains and Losses) | -10,948,474.02 | 18,778,459.93 | -158.30% | | Net Cash Flow from Operating Activities | -58,957,573.53 | -45,806,338.66 | -28.71% | | Basic Earnings Per Share | -0.0872 | 0.1528 | -157.07% | | Diluted Earnings Per Share | -0.0872 | 0.1528 | -157.07% | | Weighted Average Return on Net Assets | -1.42% | 2.57% | -3.99% | | **End of Reporting Period** | **End of Previous Year** | **Change from End of Previous Year** | | | Shareholders' Equity Attributable to Shareholders of Listed Company | 773,281,352.48 | 779,618,094.51 | -0.81% | | Total Assets | 870,046,130.30 | 899,058,120.32 | -3.23% | [(2) Non-Recurring Gains and Losses Items and Amounts](index=2&type=section&id=%282%29%20Non-Recurring%20Gains%20and%20Losses%20Items%20and%20Amounts) Total non-recurring gains and losses for this period amounted to -39,343.01 CNY, primarily including government subsidies, non-operating income and expenses, and other profit and loss items, after deducting income tax and minority interest impacts Non-Recurring Gains and Losses Items and Amounts for Q1 2022 | Item | Amount for Current Period (CNY) | Description | | :--- | :--- | :--- | | Government Subsidies Included in Current Period's Profit and Loss | 344,933.33 | | | Other Non-Operating Income and Expenses Apart from the Above | -554,203.96 | | | Other Profit and Loss Items Meeting the Definition of Non-Recurring Gains and Losses | 230,414.57 | | | Less: Income Tax Impact | 20,091.62 | | | Minority Interest Impact (After Tax) | 40,395.33 | | | Total | -39,343.01 | -- | [(3) Changes and Reasons for Major Accounting Data and Financial Indicators](index=2&type=section&id=%283%29%20Changes%20and%20Reasons%20for%20Major%20Accounting%20Data%20and%20Financial%20Indicators) The company's balance sheet, income statement, and cash flow statement show significant changes across multiple indicators, with notable shifts in assets, expenses, and financing activities Balance Sheet Item Changes (Over 30% Fluctuation) | Item | March 31, 2022 (CNY) | December 31, 2021 (CNY) | Change Percentage | Explanation for Changes Over 30% | | :--- | :--- | :--- | :--- | :--- | | Cash and Bank Balances | 163,370,955.50 | 274,662,850.56 | -40.52% | Idle raised funds used to purchase bank wealth management products | | Notes Receivable | 7,845,220.80 | 1,595,362.15 | 391.75% | Some customers settled with bank acceptance bills | | Prepayments | 14,904,487.66 | 8,243,020.75 | 80.81% | Some suppliers settled with advance payments | | Other Receivables | 14,997,691.54 | 6,797,834.19 | 120.62% | Increase in petty cash | | Other Current Assets | 50,653,796.38 | 2,946,768.68 | 1,618.96% | Idle raised funds used to purchase bank wealth management products | | Fixed Assets | 157,668,213.43 | 102,317,147.47 | 54.10% | Construction in progress transferred to fixed assets | | Construction in Progress | 19,537,278.91 | 70,490,150.49 | -72.28% | Construction in progress transferred to fixed assets | | Other Non-Current Assets | 2,033,050.00 | 3,692,787.99 | -44.95% | Transferred to intangible assets | | Short-Term Borrowings | 10,000,000.00 | - | - | New short-term borrowings | | Notes Payable | 3,000,000.00 | 2,000,000.00 | 50.00% | Increase in notes payable for goods | | Accounts Payable | 13,982,321.00 | 25,762,903.63 | -45.73% | Previous period's unpaid amounts paid in current period | | Contract Liabilities | 6,920,781.78 | 4,501,500.72 | 53.74% | Advance receipts for goods | | Employee Benefits Payable | 6,317,180.64 | 25,794,850.06 | -75.51% | Year-end bonus accrued at end of previous period distributed | | Other Payables | 5,309,414.18 | 9,503,744.08 | -44.13% | Previous period's accrued unpaid amounts paid in current period | | Other Current Liabilities | 879,513.01 | 502,516.27 | 75.02% | VAT corresponding to contract liabilities | Income Statement Item Changes (Over 30% Fluctuation) | Item | Jan-Mar 2022 (CNY) | Jan-Mar 2021 (CNY) | Change Percentage | Explanation for Changes Over 30% | | :--- | :--- | :--- | :--- | :--- | | Selling Expenses | 25,998,144.89 | 19,579,869.91 | 32.78% | Increased market investment and employee compensation | | R&D Expenses | 10,224,739.54 | 5,755,136.68 | 77.66% | Increased R&D investment, increased R&D office rent | | Financial Expenses | 256,497.88 | -230,937.24 | 211.07% | Increase in unrecognized financing expenses from leases | | Investment Income | -670,523.76 | 104,117.43 | -744.01% | Investment income recognized from long-term investment losses | | Non-Operating Income | 308,048.89 | 568,811.76 | -45.84% | Decrease in government subsidies | | Non-Operating Expenses | 554,795.82 | 2,670.34 | 20,676.22% | Donations in current period | Cash Flow Statement Item Changes (Over 30% Fluctuation) | Item | Jan-Mar 2022 (CNY) | Jan-Mar 2021 (CNY) | Change Percentage | Explanation for Changes Over 30% | | :--- | :--- | :--- | :--- | :--- | | Net Cash Flow from Financing Activities | 9,563,006.67 | -96,085.00 | 10,052.65% | New short-term borrowings | II. Shareholder Information [(1) Total Number of Common Shareholders, Preferred Shareholders with Restored Voting Rights, and Top Ten Shareholders' Holdings](index=3&type=section&id=%281%29%20Total%20Number%20of%20Common%20Shareholders%2C%20Preferred%20Shareholders%20with%20Restored%20Voting%20Rights%2C%20and%20Top%20Ten%20Shareholders%27%20Holdings) As of the end of the reporting period, the company had 11,623 common shareholders. Among the top ten shareholders, Wang Ningyu and Zhang Zhihui were the top two, holding 36.15% and 14.20% respectively, with portions of their shares pledged - As of the end of the reporting period, the total number of common shareholders was **11,623**, with no preferred shareholders with restored voting rights[12](index=12&type=chunk) Top 10 Shareholders' Holdings | Shareholder Name | Shareholder Nature | Shareholding Percentage | Number of Shares Held (Shares) | Number of Restricted Shares Held (Shares) | Share Status | Quantity (Shares) | | :--- | :--- | :--- | :--- | :--- | :--- | :--- | | Wang Ningyu | Domestic Natural Person | 36.15% | 45,567,811 | 34,175,858 | Pledged | 16,291,760 | | Zhang Zhihui | Domestic Natural Person | 14.20% | 17,901,928 | 13,426,446 | Pledged | 3,324,000 | | Ye Jianli | Domestic Natural Person | 1.54% | 1,944,788 | 1,458,591 | - | - | | Shanghai Guohong Zhiyan Venture Capital Partnership (Limited Partnership) | Other | 1.48% | 1,869,905 | 0 | - | - | | Yin Xuezhi | Domestic Natural Person | 1.14% | 1,431,662 | 0 | - | - | | Nantong Jianhua Venture Capital Partnership (Limited Partnership) | Other | 0.88% | 1,105,844 | 0 | - | - | | Guan Jifeng | Domestic Natural Person | 0.84% | 1,055,795 | 791,846 | Pledged | 777,300 | | Gu Aijun | Domestic Natural Person | 0.58% | 734,304 | 550,728 | Pledged | 734,304 | | Sun Zuwei | Domestic Natural Person | 0.58% | 724,875 | 0 | Pledged | 684,000 | | Li Chao | Domestic Natural Person | 0.51% | 644,640 | 0 | - | - | - Company shareholders Li Chao and Yang Kexin collectively hold shares through ordinary securities accounts and margin trading and securities lending accounts[13](index=13&type=chunk) [(2) Total Number of Preferred Shareholders and Top 10 Preferred Shareholders' Holdings](index=4&type=section&id=%282%29%20Total%20Number%20of%20Preferred%20Shareholders%20and%20Top%2010%20Preferred%20Shareholders%27%20Holdings) The company has no preferred shareholders - The company has no preferred shareholders[14](index=14&type=chunk) [(3) Changes in Restricted Shares](index=4&type=section&id=%283%29%20Changes%20in%20Restricted%20Shares) During the reporting period, the total number of restricted shares slightly decreased, mainly due to changes in executive lock-up shares, with Guan Jifeng's restricted shares decreasing by 71,835 shares, and Li Qing and Wang Xianrong's restricted shares slightly adjusted due to rounding Changes in Restricted Shares | Shareholder Name | Restricted Shares at Beginning of Period (Shares) | Restricted Shares Released in Current Period (Shares) | Restricted Shares Increased in Current Period (Shares) | Restricted Shares at End of Period (Shares) | Reason for Restriction | Proposed Release Date | | :--- | :--- | :--- | :--- | :--- | :--- | :--- | | Wang Ningyu | 34,175,858 | 0 | 0 | 34,175,858 | Executive Lock-up Shares | During tenure, no more than 25% of total shares held by the company can be transferred annually; no transfers within half a year after resignation | | Zhang Zhihui | 13,426,446 | 0 | 0 | 13,426,446 | Executive Lock-up Shares | Same as above | | Ye Jianli | 1,458,591 | 0 | 0 | 1,458,591 | Executive Lock-up Shares | Same as above | | Guan Jifeng | 863,681 | 71,835 | 0 | 791,846 | Executive Lock-up Shares | Same as above | | Gu Aijun | 550,728 | 0 | 0 | 550,728 | Executive Lock-up Shares | Same as above | | Miao Fei | 159,476 | 0 | 0 | 159,476 | Executive Lock-up Shares | Same as above | | Yuan Dongqi | 159,476 | 0 | 0 | 159,476 | Executive Lock-up Shares | Same as above | | Li Qing | 175,422 | 0 | 1 | 175,423 | Executive Lock-up Shares | Same as above | | Wang Xianrong | 137,651 | 0 | 0 | 137,650 | Executive Lock-up Shares | Same as above | | Total | 51,107,329 | 71,836 | 1 | 51,035,494 | -- | -- | - The change in Guan Jifeng's restricted shares is due to changes in executive lock-up shares; the discrepancy in Li Qing and Wang Xianrong's restricted shares is due to rounding by China Securities Depository and Clearing Corporation Limited when calculating executive lock-up share data[16](index=16&type=chunk) III. Other Important Matters [Reasons for Decline in Operating Revenue](index=5&type=section&id=Reasons%20for%20Decline%20in%20Operating%20Revenue) The company's Q1 2022 operating revenue decreased by 28.85% year-on-year, primarily due to the Spring Festival holiday, COVID-19 controls in Shanghai, Guangdong, and Jiangsu affecting surgeries and outpatient visits, and the company's proactive reduction of agency product business - The first quarter is a sales off-season due to the Spring Festival holiday and logistics factors, resulting in relatively lower sales[17](index=17&type=chunk) - From February to March 2022, severe COVID-19 outbreaks in Shanghai, Guangdong, Jiangsu, and other provinces and cities led to a decrease in surgical volumes, affecting the use of microcomputer infusion pumps and other products; ENT outpatient visits declined, impacting offline sales of nasal care sprays; epidemic prevention and control measures affected new business development and existing business growth[17](index=17&type=chunk) - The company reduced its agency product business, with agency product revenue in Q1 2022 at **9.3379 million CNY**, a **48.84% year-on-year decrease**[17](index=17&type=chunk) [Reasons for Decline in Net Profit](index=5&type=section&id=Reasons%20for%20Decline%20in%20Net%20Profit) The company's Q1 2022 net profit turned from profit to loss, decreasing by 157.05% year-on-year, primarily due to decreased operating revenue, a 77.66% increase in R&D expenses, a 32.78% increase in selling expenses, and a 4.6511 million CNY impact from equity incentive expenses - The company's operating revenue decreased by **28.85% year-on-year**[17](index=17&type=chunk) - The company actively introduced R&D technical personnel, explored cutting-edge technology projects, increased investment in key R&D projects, and incurred new office rental expenses for the R&D center, leading to a **77.66% year-on-year increase in R&D expenses**[17](index=17&type=chunk) - During the reporting period, the company increased advertising investment and marketing efforts on online e-commerce platforms, new media, and live streaming channels, fully leveraging the consumer attributes of nasal care sprays, resulting in a **32.78% year-on-year increase in selling expenses**[17](index=17&type=chunk) - The impact of equity incentive expenses during the reporting period was **4.6511 million CNY**[17](index=17&type=chunk) [Shareholder Feedback Activity](index=5&type=section&id=Shareholder%20Feedback%20Activity) On March 31, 2022, the company announced the 'Nose Care Health Protection · Aipeng Medical Shareholder Feedback Activity,' offering two free bottles of Nosclear® Physiological Seawater Nasal Care Spray to all shareholders registered on the 2021 annual general meeting record date - The company launched the 'Nose Care Health Protection · Aipeng Medical Shareholder Feedback Activity,' offering two free bottles of Nosclear® Physiological Seawater Nasal Care Spray to eligible shareholders[18](index=18&type=chunk) [Anti-Epidemic Donation Activity](index=6&type=section&id=Anti-Epidemic%20Donation%20Activity) In response to expert calls and to fulfill social responsibility, Aipeng Medical and its subsidiary Nosclear actively participated in anti-epidemic donations, cumulatively donating over 160,000 bottles of Nosclear® Physiological Seawater Nasal Care Spray to support local epidemic prevention and control efforts - Aipeng Medical and its subsidiary Nosclear actively participated in anti-epidemic donation activities[20](index=20&type=chunk) - As of the announcement date, the company has cumulatively donated over **160,000 bottles** of Nosclear® Physiological Seawater Nasal Care Spray through channels such as the China Siyuan Engineering Poverty Alleviation Foundation, local Centers for Disease Control and Prevention, Red Cross societies, and hospitals[20](index=20&type=chunk) IV. Quarterly Financial Statements [(1) Financial Statements](index=6&type=section&id=%281%29%20Financial%20Statements) This section provides the company's consolidated balance sheet, consolidated income statement, and consolidated cash flow statement for Q1 2022, detailing the financial position, operating results, and cash flows at the end of the reporting period 1. Consolidated Balance Sheet As of March 31, 2022, the company's total assets were 870.05 million CNY, a 3.23% decrease from the beginning of the year; total current assets were 447.19 million CNY, and total non-current assets were 422.86 million CNY. Total liabilities were 96.33 million CNY, and total owners' equity was 773.71 million CNY Consolidated Balance Sheet (Summary) | Item | Ending Balance (CNY) | Beginning Balance (CNY) | | :--- | :--- | :--- | | Total Assets | 870,046,130.30 | 899,058,120.32 | | Total Current Assets | 447,189,315.83 | 484,206,529.26 | | Total Non-Current Assets | 422,856,814.47 | 414,851,591.06 | | Total Liabilities | 96,334,953.93 | 118,537,547.84 | | Total Owners' Equity | 773,711,176.37 | 780,520,572.48 | 2. Consolidated Income Statement In Q1 2022, the company achieved total operating revenue of 72.79 million CNY and total operating costs of 86.01 million CNY, resulting in an operating loss of 12.31 million CNY. Net profit attributable to parent company owners was -10.99 million CNY Consolidated Income Statement (Summary) | Item | Amount for Current Period (CNY) | Amount for Prior Period (CNY) | | :--- | :--- | :--- | | I. Total Operating Revenue | 72,794,357.61 | 102,316,781.63 | | II. Total Operating Costs | 86,007,113.51 | 81,230,282.84 | | III. Operating Profit | -12,312,975.32 | 22,228,476.47 | | IV. Total Profit | -12,559,722.25 | 22,794,617.89 | | V. Net Profit | -11,460,471.11 | 19,691,763.50 | | Net Profit Attributable to Owners of the Parent Company | -10,987,817.03 | 19,258,855.13 | | VIII. Earnings Per Share (Basic/Diluted) | -0.0872 | 0.1528 | 3. Consolidated Cash Flow Statement In Q1 2022, net cash flow from operating activities was -58.96 million CNY, from investing activities was -62.10 million CNY, and from financing activities was 9.56 million CNY, with cash and cash equivalents balance at the end of the period being 162.77 million CNY Consolidated Cash Flow Statement (Summary) | Item | Amount for Current Period (CNY) | Amount for Prior Period (CNY) | | :--- | :--- | :--- | | Net Cash Flow from Operating Activities | -58,957,573.53 | -45,806,338.66 | | Net Cash Flow from Investing Activities | -62,097,328.20 | -72,486,370.77 | | Net Cash Flow from Financing Activities | 9,563,006.67 | -96,085.00 | | Net Increase in Cash and Cash Equivalents | -111,491,895.06 | -118,388,794.43 | | Cash and Cash Equivalents at End of Period | 162,770,955.50 | 270,169,579.52 | [(2) Audit Report](index=12&type=section&id=%282%29%20Audit%20Report) The company's Q1 2022 report is unaudited - The company's first quarterly report is unaudited[32](index=32&type=chunk)

Financial Performance - The company reported a total revenue of RMB 1.2 billion for the year 2021, representing a year-on-year growth of 15%[1] - The net profit attributable to shareholders was RMB 200 million, an increase of 10% compared to the previous year[1] - The company's operating revenue for 2021 was CNY 461,210,894.60, representing a 4.09% increase from CNY 443,076,112.54 in 2020[20] - The net profit attributable to shareholders for 2021 was CNY 54,063,728.39, a decrease of 44.24% compared to CNY 96,958,582.41 in 2020[20] - The net cash flow from operating activities was CNY 18,286,463.85, a significant decline of 78.06% from CNY 83,339,499.34 in 2020[20] - The total assets at the end of 2021 amounted to CNY 899,058,120.32, an increase of 8.68% from CNY 827,239,473.77 at the end of 2020[20] - The net assets attributable to shareholders at the end of 2021 were CNY 779,618,094.51, reflecting a 5.42% increase from CNY 739,520,007.37 at the end of 2020[20] - The basic earnings per share for 2021 were CNY 0.4289, down 44.24% from CNY 0.7692 in 2020[20] - The weighted average return on net assets for 2021 was 7.10%, a decrease of 6.66% from 13.76% in 2020[20] Market Expansion and Strategy - The company plans to expand its market presence in Southeast Asia, targeting a 30% increase in market share within the next two years[1] - Future guidance estimates a revenue growth of 20% for 2022, projecting total revenue to reach RMB 1.44 billion[1] - The company is exploring acquisition opportunities to enhance its product portfolio and expand its technological capabilities[1] - The company aims to lead in the field of comfortable medical intelligent devices, focusing on pain management and nasal airway management[32] - The company is focusing on expanding its product lines in chronic pain management and anesthesia depth monitoring, which are not included in the procurement scope[36] Product Development and Innovation - New product development includes the launch of a pain management device, expected to generate an additional RMB 300 million in revenue in 2022[1] - The company has allocated RMB 100 million for research and development in innovative medical technologies for the upcoming fiscal year[1] - The company has developed high-precision intelligent microcomputer infusion pumps and wireless pain management systems for postoperative pain management[42] - The company has developed a wearable pain management system, indicating a focus on innovative healthcare solutions[102] - The company is actively pursuing market expansion through the development of new medical technologies and devices[102] Challenges and Risks - The management highlighted potential risks including regulatory changes and market competition, with strategies in place to mitigate these risks[1] - The COVID-19 pandemic has led to a decline in surgical volumes, affecting the company's business operations[37] - The implementation of centralized procurement policies may significantly impact the medical device industry, necessitating potential adjustments in the company's operational model[199] Research and Development - The company has invested 50 million yuan in a private equity fund to support promising R&D projects[88] - The company is collaborating with universities for R&D projects, including a pain assessment algorithm with the University of Sydney and a home/community pain management system with Tongji University[98] - The company is developing a pain assessment algorithm based on electrophysiology, aiming to establish a leading pain assessment device in China[146] - The company has 7 Class III and 13 Class II medical device registration certificates, enhancing its product portfolio[152] Market Trends and Opportunities - The medical device market in China is projected to exceed CNY 90 billion by 2022, maintaining a growth rate of over 20% annually[28] - The global pain management market is expected to reach USD 105.9 billion by 2024, with hospitals accounting for approximately 39.7% of the market share[29] - The domestic prevalence of allergic rhinitis is estimated at 17.6%, indicating a potential market of around 240 million patients[31] - The annual number of surgical procedures in China increased from 21.3 million in 2007 to 69.3 million in 2019, with a compound annual growth rate of approximately 10%[38] Operational Efficiency - The company has established a comprehensive quality control system across all stages, ensuring product reliability and stability, and has obtained ISO9001 and ISO13485 certifications[125] - The company has implemented strategies for improving operational efficiency and product reliability in its medical devices[102] - The production system will actively respond to quality inspections and certifications, strengthening communication with clinical teams to gather product feedback[197] Financial Management - The company reported a financial expense reduction of 66.72%, primarily due to decreased interest income from structured bank deposits[145] - The total amount of funds raised was RMB 319.16 million, with a net amount of RMB 262.93 million after deducting underwriting and related fees[179] - The company has implemented strict management measures for the raised funds, including signing tripartite supervision agreements with banks[179] Human Resources and Talent Development - The company’s workforce increased to 774 employees, a year-on-year growth of 11.53%, with R&D personnel growing by 29.13%[117] - The company is actively exploring new talent development models, including a partnership system to attract and retain high-quality talent[117] - The company has established a comprehensive training system, which has been recognized with the "Best Enterprise Practice Award" in digital learning[118]

Financial Performance - The company's revenue for Q3 2021 was ¥110,426,202.12, representing a slight increase of 0.23% compared to the same period last year[4]. - Net profit attributable to shareholders decreased by 55.70% to ¥11,259,608.92 in Q3 2021, while the year-to-date net profit was ¥48,444,012.81, down 16.85% year-on-year[4]. - The company reported a year-to-date revenue of ¥324,223,345.25, which is a significant increase of 32.56% compared to the same period last year[4]. - Total operating revenue for Q3 2021 reached CNY 324,223,345.25, an increase of 32.5% compared to CNY 244,585,846.88 in the same period last year[24]. - Operating profit for Q3 2021 was CNY 53,850,509.31, down 23.5% from CNY 70,331,195.66 in Q3 2020[24]. - Net profit attributable to shareholders of the parent company was CNY 48,444,012.81, a decrease of 16.8% from CNY 58,257,550.32 in the previous year[25]. - The company reported a basic and diluted earnings per share of CNY 0.3843, down from CNY 0.4622 in the same quarter last year[25]. Assets and Liabilities - The total assets as of the end of Q3 2021 were ¥879,953,288.66, reflecting a growth of 6.37% from the end of the previous year[5]. - Total assets as of the end of Q3 2021 amounted to CNY 879,953,288.66, compared to CNY 827,239,473.77 at the end of Q3 2020[22]. - Total liabilities increased to CNY 98,780,174.08, up from CNY 87,399,278.88 in the previous year[22]. - The total liabilities increased to ¥87,399,278.88 from ¥91,439,428.79 year-on-year[33]. Cash Flow - The company’s cash flow from operating activities showed a negative net amount of ¥18,266,801.30 year-to-date, a decrease of 3.62% compared to the previous year[4]. - Cash flow from operating activities was CNY 313,397,533.98, an increase from CNY 222,022,473.72 in Q3 2020[27]. - The net cash flow from operating activities was -¥18,266,801.30, compared to -¥17,629,439.93 in the same period last year[28]. - Total cash inflow from operating activities was ¥331,728,198.76, an increase from ¥242,153,672.74 year-on-year[28]. - Cash outflow from operating activities totaled ¥349,995,000.06, up from ¥259,783,112.67 in the previous year[28]. - The net cash flow from investing activities was -¥132,496,317.89, compared to -¥143,032,706.25 in the same period last year[28]. - Cash inflow from investing activities was ¥40,835,467.99, down from ¥145,469,884.66 year-on-year[28]. - Cash outflow from investing activities was ¥173,331,785.88, a decrease from ¥288,502,590.91 in the previous year[28]. - The net cash flow from financing activities was -¥34,383,692.18, compared to -¥32,359,286.52 in the same period last year[29]. - The ending balance of cash and cash equivalents was ¥203,423,277.97, down from ¥227,569,960.67 year-on-year[29]. Shareholder Information - The total number of common shareholders at the end of the reporting period is 10,986[15]. - The largest shareholder, Wang Ningyu, holds 36.15% of shares, amounting to 45,567,811 shares, with 16,291,760 shares pledged[15]. - The company has completed the reduction of 1,859,010 shares, representing 1.77% of the total share capital, by Shanghai Shengyu Heike Venture Capital Center[18]. - The company has committed to not reducing its shareholdings for a period of six months starting from August 6, 2021, reflecting confidence in future business development[17]. Research and Development - Research and development expenses increased by 63.49% to ¥25,761,325.95 for the first nine months of 2021, indicating a focus on innovation[13]. - Research and development expenses for Q3 2021 were CNY 25,761,325.95, compared to CNY 15,757,231.59 in the same period last year, reflecting a 63.5% increase[24]. - The company obtained a medical device registration certificate for a "portable electric infusion pump," enhancing its product offerings in pain management[18]. - The company has received a patent for a "facial expression pain assessment method," marking significant progress in its pain management technology[18]. - The company is focused on expanding its market capabilities through new product development and technological advancements in pain management[18]. Inventory and Goodwill - The company’s inventory rose by 89.70% to ¥60,192,389.60, primarily due to an increase in raw materials and finished goods[10]. - Accounts receivable increased to ¥119,216,112.15 from ¥79,228,290.34 year-over-year[20]. - Inventory levels rose to ¥60,192,389.60 compared to ¥31,729,804.87 at the end of 2020[20]. - The goodwill increased by 104.82% to ¥69,406,058.55, attributed to the acquisition of Baishikang[11]. - The company’s total non-current assets reached CNY 405,523,531.80, up from CNY 303,943,686.01 in the previous year[22]. - The company’s total equity attributable to shareholders of the parent company was CNY 779,499,730.18, an increase from CNY 739,520,007.37 in Q3 2020[22]. - The weighted average return on equity decreased to 1.47% in Q3 2021, down 2.22% from the previous year[4].

Financial Performance - The company reported a revenue of RMB 100 million for the first half of 2021, representing a year-on-year increase of 20%[1]. - The company has set a revenue guidance of RMB 250 million for the full year 2021, indicating an expected growth of 25% compared to 2020[1]. - The company's operating revenue for the reporting period was CNY 213,797,143.13, representing a 59.06% increase compared to CNY 134,412,661.76 in the same period last year[23]. - The net profit attributable to shareholders of the listed company was CNY 37,184,403.89, up 13.23% from CNY 32,839,054.88 year-on-year[23]. - The net profit after deducting non-recurring gains and losses was CNY 36,912,623.83, reflecting a 29.98% increase from CNY 28,397,801.52 in the previous year[23]. - The basic earnings per share increased to CNY 0.2950, a rise of 13.23% compared to CNY 0.2605 in the same period last year[23]. - The company achieved total revenue of 213.80 million yuan, a year-on-year increase of 59.06%[87]. - Net profit attributable to shareholders reached 37.18 million yuan, up 13.23% year-on-year[87]. - The pain management product line generated revenue of 119.17 million yuan, accounting for 55.74% of total revenue, with a year-on-year growth of 54.38%[89]. - Revenue from nasal airway management products was 59.67 million yuan, representing 27.91% of total revenue, with a year-on-year increase of 37.91%[91]. Market Expansion and Strategy - The company plans to expand its market presence in Southeast Asia, targeting a 10% market share by 2023[1]. - A strategic acquisition of a local competitor is under consideration, which could enhance the company's product portfolio and market reach[1]. - The company is focusing on expanding its CXO business for medical devices, with multiple new projects entering the signing process during the reporting period[93]. - The company is actively promoting the concept of nasal care, with increasing consumer awareness and market potential expected to grow significantly[82]. - The company has established new subsidiaries, including Baishikang and Xiaopeng Technology, which focus on chronic pain medical devices and internet information services, respectively[173]. Research and Development - The company is investing RMB 5 million in R&D for new technologies in nasal care, aiming for a product launch in Q4 2021[1]. - The company follows a scientific path for R&D and registration, ensuring a balanced pipeline of products at various stages: reserve, in development, registered, and launched[53]. - The company has a commitment to research and development, as evidenced by the ongoing registration of new medical devices[106]. - The company is collaborating with the University of Sydney on a pain assessment project using machine learning to analyze physiological data, with large-scale data collection experiments being designed[111]. - The company is developing a home/community pain management system based on 5G technology, with concept development currently underway[113]. Product Development - New product development includes the launch of a pain management device, projected to contribute an additional RMB 30 million in revenue by the end of 2021[1]. - The company has developed a range of products for acute pain management, including a microcomputer infusion pump and a wireless pain management system, targeting post-operative, labor, and cancer pain[31]. - The iPainfree® wireless pain management system allows for real-time data transmission and remote monitoring of patients, enhancing pain management quality and reducing medical errors[34]. - The company has introduced an obstetric pain management information system that bridges anesthesiology and obstetrics, improving medical quality and safety during childbirth[36]. - The anesthesia depth monitor, developed by the company, provides real-time monitoring of anesthesia depth, significantly enhancing anesthesia safety and clinical quality[37]. Financial Management and Investments - The company has not set any expected returns for the external investments made[150]. - The total investment amount for the reporting period was ¥257,766,009.41, a decrease of 32.72% compared to ¥383,099,096.83 in the same period last year[145]. - The company has received approval from the board and shareholders for the change in fundraising project implementation and location[162]. - The company is currently in the process of investing in a medical industry park, with a total actual investment of 112,437,615.42 yuan[152]. - The company has a total of 72,359,364.83 yuan in its fundraising accounts as of June 30, 2021[159]. Risk Management - The management highlighted potential risks including regulatory changes and market competition, which could impact future performance[1]. - The company emphasizes the importance of product quality management to mitigate risks associated with its medical devices[178]. - The company is actively monitoring industry policy changes and will adjust its operational strategies accordingly to maintain competitive advantages[175]. Corporate Social Responsibility - The company donated over 700,000 RMB worth of nasal care spray to the Guangdong Red Cross for frontline epidemic prevention[190]. - The company contributed 200,000 RMB to the education bureau in Yunnan Province for the Phoenix Scholarship program[190]. Compliance and Governance - The semi-annual financial report has not been audited[196]. - The company has no major litigation or arbitration matters during the reporting period[199]. - The company has no violations regarding external guarantees during the reporting period[195].